The Board of Directors of the Plasma Protein Therapeutics Association (PPTA) announced today that Amy Efantis will be its next President and Chief Executive Officer effective January 16, 2019.
| ANNAPOLIS, Md., /PRNewswire/ -- The Board of Directors of the Plasma Protein Therapeutics Association (PPTA) announced today that Amy Efantis will be its next President and Chief Executive Officer effective January 16, 2019.
Having served most recently as Vice President, Global Public Policy & Government Affairs at Biogen, Efantis joins the PPTA, the world’s leading trade association that represents more than 750 human plasma collection centers in North America and Europe as well as the manufacturers of life-saving plasma protein therapies. Speaking on behalf of the PPTA’s Global Board of Directors, David Bell, Chairman of the PPTA’s Global Board of Directors and General Counsel and Chief Innovation Officer with Grifols SA, stated: “We are very pleased that Amy has agreed to take on the leadership for the PPTA at a time of unprecedented change in health care. Continued progress in the development of vital and life-saving treatments through the development of plasma protein therapies is critically dependent on the support needed from global stakeholders around the world. Amy has been selected by our Board as we all believe she has the leadership and vision to set the course for PPTA’s future.” “I am thrilled and honored to be joining the PPTA and the vital efforts of the plasma industry,” said Efantis. She also observed that, “to represent companies whose mission is serving patients with rare diseases that can be treated through the development of plasma-derived products is a stewardship role that I embrace with humility and a deeply felt passion.” Previous to her role with Biogen, Efantis held roles with Boehringer Ingelheim, PhRMA, and worked on Capitol Hill as a Congressional Legislative Director and, prior to this role, advised Congressman Thomas Barrett (D-WI) on various House Energy & Commerce Committee issues, primarily in the healthcare policy areas. Efantis joins the PPTA following the retirement of President and CEO Jan M. Bult on December 31, 2018. Said Bell: “We have been honored to have Jan lead our organization and are deeply grateful for the extraordinary work that he and his team have contributed to the furtherance of the PPTA’s mission over these past twenty-three years. We are excited to know that Amy will build upon the excellent foundation of the Association.” About PPTA
SOURCE Plasma Protein Therapeutics Association (PPTA) |
View original content to download multimedia:
